Angiogenesis augmentation therapy for indirect revascularization of moyamoya disease using G-CSF

Angiogenesis augmentation therapy for indirect revascularization of moyamoya disease using G-CSF - EDFAPS-G

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071220048

Enrollment

Registered

2022-08-29

Start date

2022-10-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moyamoya disease Moyamoya disease, indirect revascularization, Granulocyte-Colony Stimulating Factor

Interventions

G-CSF(75 micrograms/body) is applied intraoperatively to the indirect revascularization site, and G-CSF (75 micrograms/body) is given intravenously once daily for 2 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Moyamoya disease requiring direct/indirect revascularization. 2.Age:20-60 years old. 3.Obtain informed consent by the document.

Exclusion criteria

Exclusion criteria: 1.Splenomegaly or splenic lesions on abdominal echo. 2.Leukocytosis more than 15000/mm3 3.Past histries of symptomatic intracranial hemorrhage, bleeding tendency or coagulating disorders. 4.Hyper reactivity to G-CSF. 5.Congestive heart failure or uncontrollable angina. 6.Thrombocytopenia(less than 140000/mm3) 7.Liver dysfunction(AST(GOT),ALT(GPT) more than 100 IU/L) 8.Renal dysfunction (creatinine 1.5mg/dl and more) 9.Difficult to continue this trial due to social problems, etc. 10.Join other clinical trials. 11.Inappropriate to enroll in this trial by the judgment of the doctor.

Design outcomes

Primary

Measure	Time frame
adverse reaction within one month of G-CSF use	—

Contacts

Public ContactMotohiro Morioka

Kurume University, School of Medicine, Department of Neurosurgery

mmorioka@kurume-u.ac.jp+81-942-31-7570

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026